Has the Canadian Healthtech Industry valuation changed over the past few years?

Investors are pessimistic on the Canadian Healthcare Services industry, indicating that they anticipate long term growth rates will be lower than they have historically. The 3-year average PS ratio of 7.7x is higher than the industry's current PS ratio of 6.3x.

Which industries have driven the changes within the Canadian Healthcare industry?

There are no additional sub-industries under this industry.

Canadian (TSX) Healthtech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 21 Aug 2026	CA$1.3b	CA$208.9m	-CA$41,225,318.00	58.1x	-31.8x	6.3x
Sun, 19 Jul 2026	CA$1.9b	CA$267.1m	-CA$42,328,681.00	59.5x	-44.5x	7x
Tue, 16 Jun 2026	CA$1.9b	CA$267.0m	-CA$43,055,283.00	56.7x	-44.5x	7.2x
Thu, 14 May 2026	CA$2.0b	CA$241.0m	-CA$21,805,355.00	95x	-92.7x	8.4x
Sat, 11 Apr 2026	CA$1.7b	CA$218.2m	-CA$21,945,570.00	223.5x	-77.1x	7.8x
Mon, 09 Mar 2026	CA$1.7b	CA$207.3m	-CA$25,726,216.00	252x	-65.4x	8.1x
Wed, 04 Feb 2026	CA$1.7b	CA$204.2m	-CA$19,327,153.00	328.1x	-87.3x	8.3x
Fri, 02 Jan 2026	CA$1.8b	CA$204.3m	-CA$18,073,589.00	364.7x	-102.1x	9x
Sun, 30 Nov 2025	CA$1.7b	CA$205.4m	-CA$15,350,816.00	291.5x	-109.5x	8.2x
Tue, 28 Oct 2025	CA$1.9b	CA$175.8m	-CA$11,988,174.00	1117.9x	-162.4x	11.1x
Thu, 25 Sep 2025	CA$1.9b	CA$175.8m	-CA$12,143,232.00	1098.8x	-158.4x	10.9x
Sat, 23 Aug 2025	CA$1.9b	CA$172.1m	-CA$15,878,066.00	651.4x	-120.7x	11.1x
Mon, 21 Jul 2025	CA$1.7b	CA$160.9m	-CA$19,902,515.00	245.1x	-87x	10.8x
Wed, 18 Jun 2025	CA$1.7b	CA$160.9m	-CA$35,443,506.00	217.6x	-48.9x	10.8x
Fri, 16 May 2025	CA$1.4b	CA$133.8m	-CA$29,293,142.00	189x	-48.3x	10.6x
Sun, 13 Apr 2025	CA$1.3b	CA$138.7m	-CA$22,047,890.00	111.4x	-61.2x	9.7x
Tue, 11 Mar 2025	CA$1.2b	CA$131.5m	-CA$13,841,918.00	92.8x	-89.7x	9.4x
Thu, 06 Feb 2025	CA$1.4b	CA$127.2m	-CA$13,979,026.00	127.6x	-102.8x	11.3x
Sat, 04 Jan 2025	CA$1.3b	CA$127.1m	-CA$21,980,357.00	119x	-59.7x	10.3x
Mon, 02 Dec 2024	CA$1.3b	CA$127.1m	-CA$21,980,357.00	128.4x	-57.4x	9.9x
Wed, 30 Oct 2024	CA$992.3m	CA$117.8m	-CA$25,832,010.00	99.3x	-38.4x	8.4x
Fri, 27 Sep 2024	CA$903.9m	CA$117.8m	-CA$25,474,194.00	92.9x	-35.5x	7.7x
Sun, 25 Aug 2024	CA$906.3m	CA$103.4m	-CA$20,819,083.00	91.5x	-43.5x	8.8x
Tue, 23 Jul 2024	CA$840.1m	CA$111.1m	-CA$23,614,965.00	62x	-35.6x	7.6x
Thu, 20 Jun 2024	CA$846.7m	CA$120.3m	-CA$22,080,786.76	50.7x	-38.3x	7x
Sat, 18 May 2024	CA$802.4m	CA$119.6m	-CA$22,780,754.82	48.9x	-35.2x	6.7x
Mon, 15 Apr 2024	CA$734.4m	CA$212.3m	-CA$50,143,907.03	42.1x	-14.6x	3.5x
Wed, 13 Mar 2024	CA$710.1m	CA$223.9m	-CA$51,688,001.29	50.1x	-13.7x	3.2x
Fri, 09 Feb 2024	CA$658.0m	CA$220.7m	-CA$49,778,712.85	44.4x	-13.2x	3x
Sun, 07 Jan 2024	CA$580.0m	CA$221.4m	-CA$74,810,061.00	33.8x	-7.8x	2.6x
Tue, 05 Dec 2023	CA$724.5m	CA$221.9m	-CA$77,837,452.00	37x	-9.3x	3.3x
Thu, 02 Nov 2023	CA$627.9m	CA$215.1m	-CA$82,306,233.00	256.1x	-7.6x	2.9x
Sat, 30 Sep 2023	CA$677.8m	CA$214.0m	-CA$84,132,717.00	265.1x	-8.1x	3.2x
Mon, 28 Aug 2023	CA$574.0m	CA$196.7m	-CA$81,710,229.00	251.3x	-7x	2.9x


CA Market	-1.11%
Healthcare	-1.49%
Healthtech	2.90%
Healthtech	2.90%

Company	Last Price	7D	1Y	Valuation
AIRX Redwood AI	CA$1.85	27.6% +CA$41.2m	n/a	PB63.6x
HBFG Happy Belly Food Group	CA$1.66	6.4% +CA$15.1m	45.6%	PS10.1x
KDA KDA Group	CA$0.09	50.0% +CA$7.1m	-65.4%	PS50.5x
NURS Hydreight Technologies	CA$3.91	2.4% +CA$4.8m	34.8%	PE49.3x
AVCR Avricore Health	CA$0.07	27.3% +CA$1.9m	0%	PS61.4x

Announcement • Jul 30

Hydreight Technologies Inc Provides Update on Its Peptide Healthcare Platform Following Recent Fda Advisory Committee Recommendations

Hydreight Technologies Inc. provided an update on its peptide healthcare platform following the recent recommendations of the U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee. During its July 23–24, 2026 meeting, the Pharmacy Compounding Advisory Committee recommended that six peptide-related bulk drug substances--BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon--be considered for inclusion on the FDA's Section 503A Bulks List. These recommendations are advisory only, do not constitute FDA approval of any substance or finished drug product, and remain subject to the FDA's rulemaking process. Peptide-based therapies already represent a significant component of Hydreight Technologies Inc.'s existing business. Through its physician-supervised healthcare platform, the company currently supports multiple peptide-based treatment categories and has made substantial investments in physician infrastructure, pharmacy relationships, clinical protocols and technology supporting peptide-based care. The company currently supports multiple physician-supervised peptide-based treatment categories through its nationwide physician, pharmacy and technology platform, including GLP-1 therapies, Sermorelin and Ipamorelin. These peptide-based therapies form part of Hydreight Technologies Inc.'s broader personalized healthcare platform, which also includes hormone optimization, NAD+ therapies, IV wellness, sexual health, hair restoration and other physician-supervised healthcare programs. Hydreight Technologies Inc.'s peptide healthcare platform has been under development since 2019 and reflects the company's long-term strategy of building a nationwide physician-enabled healthcare infrastructure supporting compliant personalized healthcare. Since 2019, Hydreight Technologies Inc. has continued investing in its physician, pharmacy and technology infrastructure with the objective of building a scalable platform capable of supporting physician-supervised personalized healthcare across the United States. The company's healthcare ecosystem includes more than 12,000 VSDHOne licenses sold, compared to approximately 3,000 at the end of 2025; a nationwide network of 300+ licensed physicians; more than 3,000 licensed nurses operating through the Hydreight Technologies Inc. platform; a nationwide pharmacy network supporting physician-supervised healthcare programs across all 50 U.S. states; more than 45 physician-supervised treatment offerings spanning GLP-1 therapies, peptide-based treatments, hormone optimization, NAD+ therapies, IV wellness, sexual health, hair restoration and other personalized healthcare programs offered through the VSDHOne platform; and proprietary technology supporting patient onboarding, telehealth consultations, electronic prescribing, pharmacy coordination, payment processing and ongoing patient management. This infrastructure was developed well before the recent Pharmacy Compounding Advisory Committee recommendations and supports peptide-based therapies currently available through the company's platform. It also provides the operational foundation to evaluate additional physician-supervised treatment categories should future regulatory pathways permit their introduction, subject to applicable legal, clinical and regulatory requirements. Hydreight Technologies Inc. has completed medical policies, provider protocols and VSDHOne technology workflows supporting currently available physician-supervised peptide-based treatment categories, while also expanding pharmacy relationships and fulfillment capacity supporting compliant nationwide healthcare delivery. Completed initiatives include development and implementation of medical policies; completion of provider protocols; expansion of VSDHOne technology workflows; expansion of pharmacy relationships and fulfillment capacity; and clinical coordination supporting physician-supervised peptide healthcare. Hydreight Technologies Inc.'s peptide healthcare platform includes physician-supervised GLP-1 therapies, Sermorelin, Ipamorelin and other peptide-based treatment categories delivered through the company's nationwide physician, pharmacy and technology infrastructure. The company has continued expanding this platform through investments in clinical protocols, provider workflows, pharmacy relationships and VSDHOne technology, providing the operational foundation to support compliant physician-supervised peptide-based healthcare. Earlier this year, the company announced its strategic investment in Insu Therapeutics Inc., a biotechnology company developing proprietary buccal drug delivery technology for peptide and biologic medicines. Hydreight Technologies Inc.'s existing peptide-based treatment categories, nationwide physician and pharmacy infrastructure, VSDHOne platform and investment in Insu Therapeutics reflect the company's long-term strategy of building an integrated healthcare platform supporting physician-supervised personalized medicine. During its July 23–24 meeting, the Pharmacy Compounding Advisory Committee recommended six peptide-related bulk substances for potential inclusion on the Section 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon. The committee did not recommend Emideltide (DSIP). The recommendations relate solely to potential inclusion on the Section 503A Bulks List and do not constitute FDA approval. Hydreight Technologies Inc. notes that any future implementation of products involving these substances would remain subject to applicable FDA rulemaking, federal and state regulations, physician oversight, pharmacy participation and product-specific legal and clinical review.

Canadian (TSX) Healthtech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Independent Director exercised options to buy CA$143k worth of stock.

New major risk - Market cap size

Comprehensive Healthcare Systems, Inc., Annual General Meeting, Nov 12, 2026

Second quarter 2026 earnings: EPS and revenues miss analyst expectations

Hydreight Technologies Inc Provides Update on Its Peptide Healthcare Platform Following Recent Fda Advisory Committee Recommendations

Happy Belly Food Group Inc. to Report Q2, 2026 Results on Aug 25, 2026

New major risk - Share price stability

Less than half of directors are independent

ALZAI Health Corp. Validates AI-Driven Alzheimer’s Disease Risk Screening Solution On Large-Scale U.S. Patient Data

New major risk - Share price stability

No independent directors

New minor risk - Shareholder dilution

NetraMark Holdings Inc., Annual General Meeting, Jul 13, 2026